Investing.com — Cryptocurrency Injective (INJ) is on the cusp of another major milestone in its growing presence in traditional finance, as 21Shares has filed a new application with the Securities and Exchange Commission for an exchange-traded fund (ETF) based on the Injective token. This development follows closely on the heels of Canary Capital’s earlier submission for an Injective ETF, which was filed in July, and marks a significant step forward in the gradual integration of cryptocurrency into mainstream finance.
The filing by 21Shares is particularly noteworthy, given that the company ranks amongst the world’s largest exchange-traded product issuers. This new development underscores the growing interest from institutional players in integrating Injective (INJ) into their investment portfolios and reinforces Injective’s position as one of only a handful of digital assets with multiple ETF products currently in various stages of development.
"This is a major signal of growing institutional interest, making $INJ one of the few digital assets with multiple ETF products in progress," Injective stated on its official X page Monday. This level of institutional backing and recognition is a clear indicator that Injective’s innovative blockchain technology is not only being taken seriously but also actively sought by large financial players looking to tap into the immense potential offered by decentralized finance.
21Shares’ expertise in exchange-traded products is unparalleled, with a proven track record of success in navigating the complex regulatory landscape to bring new and innovative ETFs to market. Their filing signals that Injective (INJ) stands at the vanguard of the rapidly evolving cryptocurrency landscape, poised to capture an ever-increasing share of institutional investment.
Introduction to Injective
At its core, Injective is a cutting-edge Layer 1 blockchain specifically designed to cater to the growing requirements of decentralized financial services (DeFi). The technology behind Injectine addresses several pressing issues facing traditional blockchain platforms, such as infrastructure limitations that include fragmented liquidity and slow transaction finality. One of the principal innovations in the Injective architecture combines exchange primitives with CosmWasm-based composability and fast finality powered by Comet BFT, formerly known as "Tendermint BFT."
This composite framework significantly enhances the efficiency and scalability of transactions on the network, enabling it to handle an impressive 25,000 transaction per second. Such capabilities set Injective apart from its competitors in the evolving landscape of blockchain technologies.
In practice, Injective’s advanced consensus mechanism employs a delegated proof-of-stake (DPoS) approach. Through this process, token holders can delegate their tokens to validators who secure the network and participate in earning rewards via staking and gas fees. While these validators collect commissions from these rewards, they also contribute to maintaining the integrity of the Injective blockchain.
Founding and Development
The Injective Network has a storied history that dates back precisely five years to its launch on October 20, 2020. The genesis block was accompanied by an initial supply of 100 million INJ tokens, allocated across several key segments. These allocations included 20% for the founding team, 6% for seed sale participants, and a further 16.67% distributed amongst private sale investors. Binance Launchpad saw 9% go towards its participants. In addition to these allocations, specific amounts were set aside for ecosystem development (36.33%), community growth (10%), and advisors (2%).
Over time, the full genesis token supply of 100 million INJ tokens became fully unlocked in January 2024, giving investors broader access and the ability to participate more directly in the network’s governance via staking.
Market Performance
Market capitalization is one indicator of a cryptocurrency’s standing within the wider market. As of September 9, 2025, Injective boasted an impressive market capitalization of approximately $1.4 billion, underscoring its presence and influence among investors.
Despite these significant indicators of success, the growth of Injective does not go unchallenged by critics or competitors within the space. However,Injective’s innovative technology and sustained institutional interest have propelled it to a status where mere participation in emerging financial ecosystems is becoming as much a part of mainstream finance as investing itself.
Conclusion
The filing of 21Shares for an Injective ETF marks yet another pivotal step towards greater integration of cryptocurrencies into the world of traditional finance. Through this recognition, the spotlight continues to be cast on the forward-thinking blockchain technology provided by Injective.
With growing interest from institutional players and continued advancements in its innovative architecture, Injective remains poised at the forefront of a rapidly evolving landscape.